Citations Appearing in 2015

  1. Aitken, S.L., J. Altshuler, D.J. Guervil, E.B. Hirsch, L.L. Ostrosky-Zeichner, C.D. Ericsson and V.H. Tam. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. International Journal of Antimicrobial Agents 45(5): 541-544, 2015.
  2. Al Nakeeb, Z., V. Petraitis, J. Goodwin, R. Petraitiene, T.J. Walsh and W.W. Hope. Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex and Liposomal Amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 59(5): 2735-2745, 2015.
  3. Baek, I.H., B.Y. Lee, J. Kang and K.I. Kwon. Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. Journal of Veterinary Pharmacology and Therapeutics 38(2): 199-202, 2015.
  4. Bhavnani, S.M., P.G. Ambrose, J.P. Hammel, C.M. Rubino and G.L. Drusano. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints to Support Risk versus Benefit Considerations. Antimicrob Agents Chemother 60(3): 1600-1607, 2015.
  5. Biliouris, K., M. Lavielle and M.N. Trame. MatVPC: A User-friendly Matlab-based tool for the simulation and evaluation of systems pharmacology models. CPT: Pharmacometrics & Systems Pharmacology 4(9): 547-557, 2015.
  6. Bowers, D.R., H. Cao, J. Zhou, K.R. Ledesma, D. Sun, O. Lomovskaya and V.H. Tam. Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumannii. Antimicrob Agents Chemother 59(5): 2720-2725, 2015.
  7. Brown, A.N., J.R. Adams, D.L. Baluya and G.L. Drusano. Pharmacokinetic Determinants of Virological Response to Raltegravir in the In vitro Pharmacodynamic Hollow Fiber Infection Model (HFIM) System. Antimicrob Agents Chemother 59(7): 3771-3777, 2015.
  8. Brown, A.N., G.L. Drusano, J.R. Adams, J.L. Rodriquez, K. Jambunathan, D.L. Baluya, . . .and A. Louie. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy. mBio 6(6): 1741-1751, 2015.
  9. Casapao, A.M., T.P. Lodise, S. Davis, K.C. Claeys, R. Kullar, D.P. Levine and M.J. Rybak. The Association between the Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrob Agents Chemother 59(6): 2978-2985, 2015.
  10. Chadha, G. and M. Morris. Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. The AAPS Journal 17(4): 1-11, 2015.
  11. . An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. The AAPS Journal 17(6): 1464-1474, 2015.
  12. Chan, J.G.Y., A.S. Tyne, A. Pang, A.J. McLachlan, V. Perera, J.C.Y. Chan, . . .and D. Traini. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents 45(3): 319-323, 2015.
  13. Chen, X., D.C. DuBois, R.R. Almon and W.J. Jusko. Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats. Drug Metabolism and Disposition 43(6): 898-907, 2015.
  14. Christner, S., D. Clausen, J. Beumer, R. Parise, J. Guo, Y. Huang, . . .and J. Eiseman. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4–p53 interaction. Cancer Chemotherapy and Pharmacology 76(2): 287-299, 2015.
  15. Dave, R. and M. Morris. Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and l-lactate in rats. Journal of Pharmacokinetics and Pharmacodynamics 42(5): 497-513, 2015.
  16. Davis, T.L., L.S. Boyce, E. Rose, A. Swartzendruber, R. DiClemente, D. Gelaude, . . .and M. Carry. Lessons Learned From Delivering Imara, an HIV/STI Risk Reduction Intervention for African American Girls in Juvenile Detention. Health Promotion Practice 17: 31-39, 2015.
  17. Eljebari H, G.E., Bacha MM, Woillard JP, Jebabli N, et al. Cyclosporine (Equoral®) Population Pharmacokinetics and Bayesian Estimation in Tunisian Renal Transplant Recipients. Enliven: Surgery and Transplantation 1(1): 1-8, 2015.
  18. Fan, Y.-C., S.-Y. Sheu, H.-T. Lai, M.-H. Chang, P.-H. Chen, Y.-C. Lei, . . .and C.-Y. Wang. Residue Depletion Study of Danofloxacin in Cultured Tilapia (<i>Oreochromis mossambicus</i>). Journal of AOAC International 98(3): 575-579, 2015.
  19. Gadzinski, J.A., B. Philips, P. Basse, J. Guo, A. Sen Gupta, L. Bailey, . . .and J.L. Eiseman. Abstract 3313: Evaluation of silicon phthalocyanine 4 photodynamic therapy in human cervical cancer cells. Cancer Research 75(15 Supplement): 3313, 2015.
  20. Gallo, J.M. and M.R. Birtwistle. Network pharmacodynamic models for customized cancer therapy. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 7(4): 234-251, 2015.
  21. Gershkovich, P., K.M. Wasan, C. Ribeyre, F. Ibrahim and J.H. McNeill. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs in Context 4: 212-287, 2015.
  22. Glassman, P., Y. Chen and J. Balthasar. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Journal of Pharmacokinetics and Pharmacodynamics 42(5): 527-540, 2015.
  23. Gonzalez, J.M., C.A. Rodriguez, A.F. Zuluaga, M. Agudelo and O. Vesga. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. PLoS ONE 10(11): e0141872, 2015.
  24. Gumbo, T., I. Angulo-Barturen and S. Ferrer-Bazaga. Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia. Journal of Infectious Diseases 211(Suppl 3): S96-S106, 2015.
  25. Guo, J., J.O. Glass, M.B. McCarville, B.L. Shulkin, V.M. Daryani, C.F. Stewart, . . .and W.E. Reddick. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 113(9): 1282-1288, 2015.
  26. Häggström, I., J. Axelsson, C.R. Schmidtlein, M. Karlsson, A. Garpebring, L. Johansson, . . .and A. Larsson. A Monte Carlo Study of the Dependence of Early Frame Sampling on Uncertainty and Bias in Pharmacokinetic Parameters from Dynamic PET. Journal of Nuclear Medicine Technology 43(1): 53-60, 2015.
  27. Horkovics-Kovats, S., P. Brunovský, A. Pichler and J.B. Bulitta. Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation. European Journal of Pharmaceutical Sciences 78: 245-254, 2015.
  28. Hovhannisyan, A., M. Nylander, G. Wikman and A. Panossian. Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial. Journal of Athletic Enhancement 4(4): 1-19, 2015.
  29. Hu, P., J. Chen, D. Liu, X. Zheng, Q. Zhao and J. Jiang. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect. European Journal of Clinical Pharmacology 71(7): 843-850, 2015.
  30. Jelliffe, R. Optimal Methodology Is Important for Optimal Pharmacokinetic Studies, Therapeutic Drug Monitoring and Patient Care. Clinical Pharmacokinetics 54(9): 887-892, 2015.
  31. Jelliffe, R.W., A. Schumitzky, D. Bayard, X. Fu and M. Neely. Describing Assay Precision—Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. Therapeutic Drug Monitoring 37(3): 389-394, 2015.
  32. Jitmuang, A., R.L. Nation, P. Koomanachai, G. Chen, H.J. Lee, S. Wasuwattakul, . . .and C.B. Landersdorfer. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. Journal of Antimicrobial Chemotherapy 70(6): 1804-1811, 2015.
  33. Justo, J.A., S.M. Mayer, M.P. Pai, M.M. Soriano, L.H. Danziger, R.M. Novak and K.A. Rodvold. Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. Antimicrob Agents Chemother 59(7): 3956-3965, 2015.
  34. Kaucher, K.A., N.M. Acquisto, G.G. Rao, D.C. Kaufman, J.D. Huntress, A. Forrest and C.E. Haas. Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35(5): 482-488, 2015.
  35. Kiser, T.H., D.N. Fish, C.L. Aquilante, J.E. Rower, M.F. Wempe, R. MacLaren and I. Teitelbaum. Evaluation of sulfobutylether-ß-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Critical Care Journal Article 19(1): 32, 2015.
  36. Koch, G. and J. Schropp. Distributed transit compartments for arbitrary lifespan distributions in aging populations. Journal of Theoretical Biology 380: 550-558, 2015.
  37. Kuti, J.L. and D.P. Nicolau. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. International Journal of Antimicrobial Agents 45(5): 512-518, 2015.
  38. Landersdorfer, C.B., S.M. Caliph, D.M. Shackleford, D.B. Ascher and L.M. Kaminskas. PEGylated Interferon Displays Differences in Plasma Clearance and Bioavailability Between Male and Female Mice and Between Female Immunocompetent C57Bl/6J and Athymic Nude Mice. Journal of Pharmaceutical Sciences 104(5): 1848-1855, 2015.
  39. Lim, T.-P., Y. Cai, Y. Hong, E.C.Y. Chan, S. Suranthran, J.Q.-M. Teo, . . .and A.L.-H. Kwa. In-vitro Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 59(5), 2015.
  40. Lon, H.-K., D.C. DuBois, J.C. Earp, R.R. Almon and W.J. Jusko. Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. Pharmacology Research & Perspectives 3(5), 2015.
  41. Louie, A., M.T. Boyne, V. Patel, C. Huntley, W. Liu, S. Fikes, . . .and G.L. Drusano. Pharmacodynamic Evaluation of the Activities of Six Parenteral Vancomycin Products Available in the United States. Antimicrob Agents Chemother 59(1): 622-632, 2015.
  42. Ly, N.S., J.B. Bulitta, G.G. Rao, C.B. Landersdorfer, P.N. Holden, A. Forrest, . . .and B.T. Tsuji. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. Journal of Antimicrobial Chemotherapy 70(5): 1434-1442, 2015.
  43. Mahmood, A.H., X. Liu, J.E. Grice, G.A. Medley and M.S. Roberts. Using deconvolution to understand the mechanism for variable plasma concentration–time profiles after intramuscular injection. International Journal of Pharmaceutics 481(1–2): 71-78, 2015.
  44. Marchand, S., S. Bouchene, M. de Monte, L. Guilleminault, J. Montharu, M. Cabrera, . . .and L. Vecellio. Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys. Pharmaceutical Research 32(10): 3403-3412, 2015.
  45. Marchand, S., N. Grégoire, J. Brillault, I. Lamarche, P. Gobin and W. Couet. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 3. Tobramycin. Antimicrob Agents Chemother 59(10): 6646-6647, 2015.
  46. Modongo, C., J.G. Pasipanodya, N.M. Zetola, S.M. Williams, G. Sirugo and T. Gumbo. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 59(10): 6337-6343, 2015.
  47. Monterrubio, C., S. Paco, M. Vila-Ubach, E. Rodríguez, R. Glisoni, C. Lavarino, . . .and A. Carcaboso. Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. Pharmaceutical Research 32(9): 2889-2900, 2015.
  48. Morris, A.A., S.W. Mueller, J.E. Rower, T. Washburn and T.H. Kiser. Evaluation of sulfobutylether-ß-cyclodextrin (SBECD) exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 59(10): 6653-6656, 2015.
  49. Nyberg, J., C. Bazzoli, K. Ogungbenro, A. Aliev, S. Leonov, S. Duffull, . . .and F. Mentré. Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies. British Journal of Clinical Pharmacology 79(1): 6-17, 2015.
  50. O’Brien, S.H., D.L. Yee, J. Lira, N.A. Goldenberg and G. Young. UNBLOCK: An open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis. Journal of Thrombosis and Haemostasis 13(9): 1615-1622, 2015.
  51. Pai, M., P. Cojutti and F. Pea. Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. Clinical Pharmacokinetics 54(9): 933-941, 2015.
  52. Parise, R., J. Eiseman, D. Clausen, K. Kicielinski, P. Hershberger, M. Egorin and J. Beumer. Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612). Cancer Chemotherapy and Pharmacology 76(3): 537-546, 2015.
  53. Pasipanodya, J.P., R.G. Hall and T. Gumbo. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clinical Pharmacology & Therapeutics 97(3): 292-297, 2015.
  54. Patel, Y., M. Jacus, N. Boulos, J. Dapper, A. Davis, P. Vuppala, . . .and C. Stewart. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherapy and Pharmacology 75(5): 1-10, 2015.
  55. Pham, D.-D., N. Grégoire, W. Couet, C. Gueutin, E. Fattal and N. Tsapis. Pulmonary delivery of pyrazinamide-loaded large porous particles. European Journal of Pharmaceutics and Biopharmaceutics 94: 241-250, 2015.
  56. Podany, A.T., Y. Bao, S. Swindells, R.E. Chaisson, J.W. Andersen, T. Mwelase, . . .and C.V. Fletcher. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clinical Infectious Diseases 61(8): 1322-1327, 2015.
  57. Ratajczak-Enselme, M., N. Grégoire, J.-P. Estebe, G. Dollo, F. Chevanne, D. Bec, . . .and P. Le Corre. Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. Regional Anesthesia and Pain Medicine 40(6): 681-686, 2015.
  58. Reddy, M.B., K.-H. Yang, G. Rao, C.R. Rayner, J. Nie, C. Pamulapati, . . .and E.A. Govorkova. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PLoS ONE 10(10): e0138069, 2015.
  59. Roberts, J.K., C. Stockmann, A. Balch, T. Yu, R.M. Ward, M.G. Spigarelli and C.M.T. Sherwin. Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Pediatric Anesthesia 25(3): 222-230, 2015.
  60. Rodriguez, C.A., M. Agudelo, J.M. Gonzalez, O. Vesga and A.F. Zuluaga. An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics. Antimicrob Agents Chemother 59(1): 233-238, 2015.
  61. Rower, J.E., E.G. Meissner, L.C. Jimmerson, A. Osinusi, Z. Sims, T. Petersen, . . .and J.J. Kiser. Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin. Journal of Antimicrobial Chemotherapy 70(8): 2322-2329, 2015.
  62. Rubino, C.M., S.M. Bhavnani, G. Moeck, S.E. Bellibas and P.G. Ambrose. Population Pharmacokinetic Analysis for a Single 1200 mg Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials. Antimicrob Agents Chemother 59(6): 3365-3372, 2015.
  63. Rubino, C.M., B. Xue, S.M. Bhavnani, W.T. Prince, Z. Ivezic-Schoenfeld, W.W. Wicha and P.G. Ambrose. Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother 59(1): 282-288, 2015.
  64. Schuck, E., T. Bohnert, A. Chakravarty, V. Damian-Iordache, C. Gibson, C.-P. Hsu, . . .and H. Wong. Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. The AAPS Journal 17(2): 1-12, 2015.
  65. Serrano-Rodríguez, J.M., M. Gómez-Díez, M. Esgueva, C. Castejón-Riber, A. Mena-Bravo, F. Priego-Capote, . . .and A. Muñoz. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. The Veterinary Journal 28: 38-43, 2015.
  66. Sherwin, C.M.T., C. Stockmann, K. Grimsrud, D.W. Herd, B.J. Anderson and M.G. Spigarelli. Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. Pediatric Anesthesia 25(2): 211-216, 2015.
  67. Siroski, P.A., N.B. Russi, H.H. Ortega and E.A. Formentini. In vitro evaluation of synergistic activity between ciprofloxacin and broad snouted caiman serum against Escherichia coli. Research in Veterinary Science 98(0): 98-105, 2015.
  68. Sorzano, C.O.S., M.A. Pérez-De-La-Cruz Moreno, J. Burguet-Castell, C. Montejo and A.A. Ros. Cost-Constrained Optimal Sampling for System Identification in Pharmacokinetics Applications with Population Priors and Nuisance Parameters. Journal of Pharmaceutical Sciences 104(6): 2103-2109, 2015.
  69. Srivastava, S., J. Pasipanodya, C.M. Sherman, C. Meek, R. Leff and T. Gumbo. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow fiber model of intracellular Mycobacterium kansasii disease. Antimicrob Agents Chemother 59(4): 2273-2279, 2015.
  70. Tamanna, T., J. Bulitta and A. Yu. Controlling antibiotic release from mesoporous silica nano drug carriers via self-assembled polyelectrolyte coating. Journal of Materials Science: Materials in Medicine 26(2): 1-7, 2015.
  71. Thabit, A.K., D.P. Nicolau and J.L. Kuti. In vitro pharmacodynamics of human simulated exposures of telavancin against methicillin susceptible and resistant Staphylococcus aureus with and without prior vancomycin exposure. Antimicrob Agents Chemother 60(1): 222-228, 2015.
  72. Thorling, C.A., L. Jin, M. Weiss, D. Crawford, X. Liu, F.J. Burczynski, . . .and M.S. Roberts. Assessing Steatotic Liver Function after Ischemia-Reperfusion Injury by In Vivo Multiphoton Imaging of Fluorescein Disposition. Drug Metabolism and Disposition 43(1): 154-162, 2015.
  73. Vinks, A.A., C. Emoto and T. Fukuda. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clinical Pharmacology & Therapeutics 98(3): 298-308, 2015.
  74. Weiss, M. Modeling accelerated and decelerated drug release in terms of fractional release rate. European Journal of Pharmaceutical Sciences 68(0): 51-55, 2015.
  75. Weiss, M., P. Sermsappasuk and W. Siegmund. Modeling the heterogeneous intestinal absorption of propiverine extended-release. European Journal of Pharmaceutical Sciences 76(0): 133-137, 2015.
  76. White, B.P., B. Lomaestro and M.P. Pai. Optimizing the Initial Amikacin Dosage in Adults. Antimicrob Agents Chemother 59(11): 7094-7096, 2015.
  77. Winter, U., E. Buitrago, H.A. Mena, M.J. Del Sole, V. Laurent, S. Negrotto, . . .and P. Schaiquevich. Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for RetinoblastomaDigoxin in Preclinical Models for Retinoblastoma. Investigative Ophthalmology & Visual Science 56(8): 4382-4393, 2015.
  78. Wittau, M., J. Scheele, M. Kurlbaum, C. Brockschmidt, A.M. Wolf, E. Hemper, . . .and J.B. Bulitta. Population pharmacokinetics and target attainment of meropenem in plasma and tissue of morbidly obese patients after laparoscopic intraperitoneal surgery. Antimicrob Agents Chemother 59(10): 6241-6247, 2015.
  79. Wu, L., W. Zhong, J. Liu, W. Han, S. Zhong, Q. Wei, . . .and L. Tang. Human microsomal cyttrochrome P450-mediated reduction of oxysophocarpine, an active and highly toxic constituent derived from Sophora flavescens species, and its intestinal absorption and metabolism in rat. Fitoterapia 105: 26-36, 2015.
  80. Wu, T.-Y., Y. Huang, C. Zhang, Z.-Y. Su, S. Boyanapalli, T. Khor, . . .and A.-N. Kong. Pharmacokinetics and pharmacodynamics of 3,3′-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes. Journal of Pharmacokinetics and Pharmacodynamics 42(4): 401-408, 2015.
  81. Yadav, R., C.B. Landersdorfer, R.L. Nation, J.D. Boyce and J.B. Bulitta. Novel approach to optimizing synergistic carbapenem plus aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 59(4): 2286-2298, 2015.
  82. Yu, D., Y. Chen and K. Hao. The pharmacokinetic–pharmacodynamic model of telmisartan and hydrochlorothiazide on blood pressure and plasma potassium after long-term administration in spontaneously hypertensive rats. Fundamental & Clinical Pharmacology 29(6): 543-552, 2015.
  83. Zasowski, E., C.M. Bland, V.H. Tam and T.P. Lodise. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. Journal of Antimicrobial Chemotherapy 70(3): 877-881, 2015.
  84. Zhao, J., Y. Cao and W. Jusko. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharmaceutical Research 32(10): 3269-3281, 2015.
  85. Zhu, L., L. Lu, S. Zeng, F. Luo, P. Dai, P. Wu, . . .and Z. Liu. UDP-Glucuronosyltransferases 1A6 and 1A9 are the Major Isozymes Responsible for the 7-O-Glucuronidation of Esculetin and 4-Methylesculetin in Human Liver Microsomes. Drug Metabolism and Disposition 43(7): 997-983, 2015.
  86. Zhu, X., R. Straubinger and W. Jusko. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics 42(5): 477-496, 2015.